Læknablaðið - 15.02.1987, Side 19

LÆKNABLAÐIÐ
49
arrhythmias in patients with HCM. Disopyramid is
effective in the treatment of ventricular arrhythmias,
but it is not known whether it can serve as an alternative
in the treatment of arrhythmias in patients with HCM.
Ten untreated patients with HCM confirmed by 2-D and
M-mode echocardiography had Holter monitors applied
for 48 hours. They were treated with oral disopyramid
200 mgs t.d.s. for 5 days. The Holter monitoring was
then repeated. The Holter tapes were read blind.
The results show that 7 patients had serious arrhythmias
before treatment (table I). After disopyramid there was
a significant reduction in the incidence of ventricular
arrhythmias, especially ventricular tachycardia.
There is a correlation between ventricular tachycardia
and prognosis in patients with HCM. It is likely that
disopyramid may be an alternative to amiodarone in the
long term treatment of patients with HCM but this
hypotesis must be confirmed with a prospective study.
HEIMILDIR
1. Bjarnason I, Hardarson T, Jonsson S. Cardiac
arrhythmias in hypertrophic cardiomyopathy. Br
Heart J 1982; 48: 198-203.
2. Canedo MI, Frank MJ, Abdulla AM. Rhythm
disturbances in hypertrophic cardiomyopathy:
prevalence, relation to symptoms and management.
Am J Cardiol 1980; 45: 848-55.
3. McKenna WJ, Chetty S, Oakley CM, Goodwin JF.
Arrhythmia in hypertrophic cardiomyopathy:
exercise and 48 hour amulatory
electrocardiographic assessment with and without
beta adrenergic blocking therapy. Am J Cardiol
1980; 45: 1-5.
4. Savage DD, Seides SF, Maron BJ, Myers DJ,
Epstein SE. Prevalence of arrhythmias during
24-hour electrocardiographic monitoring and
exercise testing in patients with obstructive and
nonobstructive hypertrophic cardiomyopathy.
Circulation 1979; 59: 866-75.
5. McKenna WJ, England D, Doi YL, Deanfield JE,
Oakley C, Goodwin JF. Arrhythmia in
hypertrophic cardiomyopathy I: influence on
prognosis. Br Heart J 1981; 46: 168-72.
6. Maron BJ, Savage DD, Wolfson JK, Epstein SE.
Prognostic significance of 24-hour ambulatory
electrocardiographic monitoring in patients with
hypertrophic cardiomyopathy: a prospective study.
AmJCardiol 1981; 48: 252-7.
7. McKenna WJ, Deanfield J, Faruqui A, England D,
Oakley C, Goodwin JF. Prognosis in hypertrophic
cardiomyopathy: role of age and clinical,
electrocardiographic and hemodynamic features.
Am J Cardiol 1981; 47: 532-8.
8. Koga Y, Itaya K-i, Toshima H. Prognosis in
hypertrophic cardiomyopathy. Am Heart J 1984;
108: 351-9.
9. Hardarson T, De La Calzada CS, Curiel R,
Goodwin JF. Prognosis and mortality of
hypertrophic obstructive cardiomyopathy. Lancet
1973; II: 1462-7.
10. Maron BJ, Roberts WC, Edwards JE, McAllister
HA, Foley DD, Epstein SE. Sudden death in
patients with hypertrophic cardiomyopathy:
characterization of 26 patients without functional
limitation. Am J Cardiol 1978; 41: 803-10.
11. Sanderson JE, Gibson DG, Brown DJ, Goodwin
JF. Left ventricular filling in hypertrophic
cardiomyopathy. Br Heart J 1977; 39: 661-70.
12. Maron BJ, Gottdiener JS, Roberts WC, Henry WL,
Savage DD, Epstein SE. Left ventricular outflow
tract obstruction due to systolic anterior motion of
the anterior mitral leaflet in patients with concentric
left ventricular hypertrophy. Circulation 1978; 57:
527-33.
13. Glancy DL, Shepherd RL, Beiser D, Epstein SE.
The dynamic nature of left ventricular outflow
obstruction in idiopathic hypertrophic subaortic
stenosis. Ann Intern Med 1971; 75: 589-92.
14. Falicov RE, Resnekov L. Mid ventricular
obstruction in hypertrophic obstructive
cardiomyopathy. Br Heart J 1977; 39: 701-5.
15. McKenna WJ, Oakley CM, Krikler DM, Goodwin
JF. Improved survival with amiodarone in patients
with hypertrophic cardiomyopathy and ventricular
tachycardia. Br Heart J 1985; 53: 412-6.
16. McKenna WJ, Harris L, Rowland E, Kleinebenne
A, Krikler DM, Oakley CM, Goodwin JF.
Amiodarone for long-term management of patients
with hypertrophic cardiomyopathy. Am J Cardiol
1984; 54: 802-10.
17. McKenna WJ, Harris L, Perez G, Krikler DM,
Oakley CM, Goodwin JF. Arrhythmia in
hypertrophic cardiomyopathy II: comparison of
amiodarone and verapamil in treatment. Br Heart J
1981; 46: 173-8.
18. Sugrue DD, Dickie S, Myers MJ, Lavender JP,
McKenna WJ. Effect of amiodarone on left
ventricular ejection and filling in hypertrophic
cardiomyopathy assessed by radionuclide
angiography. Am J Cardiol 1984; 54: 1055-8.
19. Harris L, McKenna WJ, Rowland E, Holt DW,
Storey GCA, Krikler DM. Side effects of long-term
amiodarone therapy. Circulation 1983; 67: 4551.
20. Hardarson T. Subclinical hypertrophic
cardiomyopathy - the inconspicous rump of the
iceberg. Acta Med Scand 1984; 216: 1-2.
21. Morady F, Scheinman MM, Desai J.
Disopyramide. Ann Intern Med 1982; 96: 337-43.
22. Pollick C. Muscular subaortic stenosis
hemodynamic and clinical improvement after
disopyramide. N Engl J Med 1982; 307: 997-9.
23. Nayler WG. The pharmacology of disopyramide. J
Int Med Res 1976;4 (suppl 1): 8-12.
24. Ryan M, Lown B, Horn H. Comparison of
ventricular ectopic activity during 24-hour
monitoring and exercise testing in patients with
coronary heart disease. N Engl J Med 1975; 292:
224-9.